Speiser P, Mayerhofer K, Kucera E, Roch G, Mittelböck M, Gitsch G, Zeillinger R
Department of Obstetrics and Gynecology, University of Vienna Medical School, Austria.
Anticancer Res. 1997 Jan-Feb;17(1B):679-83.
The estrogen regulated pS2 protein and the Plasminogen Activator Inhibitor type 1 (PAI-1) have been reported as important tumor parameters both in breast and in ovarian cancer. We analysed the cytosolic concentrations of pS2 in 111 ovarian carcinoma and the cytosolic concentrations of PAI-1 in 104 ovarian cancers by RIA and ELISA. Using a cut-off level of 2 ng/mg protein we found 27% pS2+ tumors. We observed 42% PAI-1+ tumors using a out-off level of 1 ng/mg. We found a statistically significant decline in the pS2 status corresponding with an increase in the PAI-1 status from well to poor differentiation grade. The highest levels of pS2 and the lowest levels of PAI-1 were measured in borderline carcinoma. Significantly higher concentrations of pS2 were measured in mucinous over serous carcinoma. We found no significant correlation between PAI-1 and histologic subtypes, or between pS2 or PAI-1 and estrogen receptor status, progesterone receptor status, age and tumor stage. To conclude, we found pS2 and PAI-1 concentrations to be correlated with the grade of differentiation. A correlation between protein status and histologic subtypes could be observed for pS2 but not for PAI-1.
雌激素调节的pS2蛋白和1型纤溶酶原激活物抑制剂（PAI-1）已被报道为乳腺癌和卵巢癌中的重要肿瘤参数。我们通过放射免疫分析（RIA）和酶联免疫吸附测定（ELISA）分析了111例卵巢癌中pS2的胞浆浓度以及104例卵巢癌中PAI-1的胞浆浓度。使用2 ng/mg蛋白的临界值，我们发现27%的肿瘤pS2呈阳性。使用1 ng/mg的临界值，我们观察到42%的肿瘤PAI-1呈阳性。我们发现，从高分化到低分化，随着PAI-1水平的升高，pS2水平在统计学上显著下降。在交界性癌中检测到最高水平的pS2和最低水平的PAI-1。在黏液性癌中检测到的pS2浓度显著高于浆液性癌。我们发现PAI-1与组织学亚型之间、pS2或PAI-1与雌激素受体状态、孕激素受体状态、年龄和肿瘤分期之间均无显著相关性。总之，我们发现pS2和PAI-1浓度与分化程度相关。对于pS2，可以观察到蛋白状态与组织学亚型之间存在相关性，但对于PAI-1则未观察到。
